Celera Licenses Protein IP for Lung Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Celera said today that it has licensed the rights to use Medical Therapies Limited's patent portfolio for the protein midkine in its lung cancer diagnostics programs.

Under the exclusive license with Sydney-based Medical Therapies, Celera will pay up front and milestone payments and royalties on product sales over the life of the patents. Specific financial details were not disclosed by the firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.